Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.

@article{Bruijn2011CombinedKA,
  title={Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.},
  author={Menno T. de Bruijn and Dani{\"e}lle A. E. Raats and Jolien Tol and John W. J. Hinrichs and Steven Teerenstra and Cornelis J A Punt and I. H. M. Borel Rinkes and Onno W. Kranenburg},
  journal={Anticancer research},
  year={2011},
  volume={31 4},
  pages={1379-85}
}
BACKGROUND The response of colorectal tumours to chemotherapy is highly variable. Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner. Therefore, whether or not the combined mutation status of KRAS and TP53 could predict response to chemotherapy in metastatic colorectal cancer was tested. PATIENTS AND METHODS A subgroup of patients from the CAIRO2 study… CONTINUE READING